GGrantIndex
← Leaderboards

Catherine Choy Smith

University Of California, San Francisco

$4,365,274
Attributed
$4,365,274
Total exposure
3
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.1M · FY201425
$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$4,365,274 · 3

By mechanism

R01$3,662,042 · 2
K08$703,232 · 1

Top collaborators

No co-investigators on record.

Most similar at University Of California, San Francisco

Same institution · by research overlap

Others in their field

Top investigators on “American

Research focus

AmericanRelapseTyrosine Kinase InhibitorAffectSignal TransductionGenesCombined Modality TherapyResistanceMutationResponseMediatingClinical TrialsResistance MechanismOncogenicAcute Myelocytic LeukemiaMutateTranslatingPhosphotransferasesSamplingMalignant NeoplasmsNovel TherapeuticsInhibitorInhibitor TherapyBcl2 Gene

Grant awards (13)

RNA Polymerase II as a Therapeutic Target in Acute Myeloid Leukemia (AML) with RAS Signaling Activation$547,180
R01 · FY2025 · CA · contact PI
Investigating the mechanism of SHP2 and BCL2 Inhibition in Acute Myeloid Leukemia (AML)$456,661
R01 · FY2025 · CA · contact PI
RNA Polymerase II as a Therapeutic Target in Acute Myeloid Leukemia (AML) with RAS Signaling Activation$77,113
R01 · FY2025 · CA · contact PI
RNA Polymerase II as a Therapeutic Target in Acute Myeloid Leukemia (AML) with RAS Signaling Activation$523,510
R01 · FY2024 · CA · contact PI
Investigating the mechanism of SHP2 and BCL2 Inhibition in Acute Myeloid Leukemia (AML)$482,061
R01 · FY2024 · CA · contact PI
RNA Polymerase II as a Therapeutic Target in Acute Myeloid Leukemia (AML) with RAS Signaling Activation$77,113
R01 · FY2024 · CA · contact PI
RNA Polymerase II as a Therapeutic Target in Acute Myeloid Leukemia (AML) with RAS Signaling Activation$534,924
R01 · FY2023 · CA · contact PI
Investigating the mechanism of SHP2 and BCL2 Inhibition in Acute Myeloid Leukemia (AML)$412,854
R01 · FY2023 · CA · contact PI
RNA Polymerase II as a Therapeutic Target in Acute Myeloid Leukemia (AML) with RAS Signaling Activation$550,626
R01 · FY2022 · CA · contact PI
Investigating Resistance to FLT3 Inhibitors in AML$175,808
K08 · FY2017 · CA · contact PI
Investigating Resistance to FLT3 Inhibitors in AML$175,808
K08 · FY2016 · CA · contact PI
Investigating Resistance to FLT3 Inhibitors in AML$175,808
K08 · FY2015 · CA · contact PI
Investigating Resistance to FLT3 Inhibitors in AML$175,808
K08 · FY2014 · CA · contact PI